Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
353 results about "CXCR4" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
C-X-C chemokine receptor type 4 (CXCR-4) also known as fusin or CD184 (cluster of differentiation 184) is a protein that in humans is encoded by the CXCR4 gene.
Human monoclonal antibodies against human CXCR4
Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cells. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection and cancer, for screening drugs, and for diagnosing diseases or conditions associated with interactions with chemokine receptors.
Owner:GENETASTIX CORP
Methods to mobilize progenitor/stem cells
Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulaZ-linker-Z′ (1)or pharmaceutically acceptable salt thereofwherein Z is of the formulawherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1–20 atoms,Z′ is of the formula—Ar(Y)j;wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0–3; and“linker” represents a bond, alkylene (1–6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
Owner:GENZYME CORP
CRISPR/Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and lentivirus of CRISPR/Cas9 recombinant lentiviral vector
ActiveCN104480144AAvoid or delay intrusionInhibit the spread of infectionGenetic material ingredientsAntiviralsEnzyme digestionCXCR4
The invention belongs to the field of pharmaceutical and biological engineering, and relates to a CRISPR / Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and a lentivirus of the CRISPR / Cas9 recombinant lentiviral vector. The recombinant lentiviral vector is prepared by carrying out enzyme digestion on a lentiviral vectorlentiCRISPR by BsmBI and connecting into a BsmBI cohesive end-containing CXCR4 specific target sequence to recombine; the obtained CRISPR / Cas9 recombinant lentiviral vector is capable of mutating gene sequences at four different loci of ahuman immunodeficiency virusco-receptor CXCR4 and themutatuin rate is high and up to 25-75%. The cells transformed by the recombinant lentiviral vector cannot be infected by the human immunodeficiency virus. Compared with theRNAi-Knockdown, ZFN and TALEN technologies, the method has higher efficiency of suppressing the human immunodeficiency virus replication; the system is rapid to construct, simple and low in cost, is capable of preventing the invasion of the human immunodeficiency virus and is suitable for human immunodeficiency virus gene therapy.
Owner:WUHAN UNIV
Virus coat protein/receptor chimeras and methods of use
InactiveUS7311920B1Sufficient amountMethod can be usedCompound screeningApoptosis detectionCXCR4Immunodeficiency virus
The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can interact with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.
Owner:MARYLAND BIOTECH INST UNIV OF
Methods to mobilize progenitor/stem cells
Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and / or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.
Owner:GENZYME CORP
Compositions and methods for detecting and treating prostate disorders
InactiveUS7598028B2Microbiological testing/measurementBiological material analysisDiseaseEccentric hypertrophy
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and / or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).
Owner:RGT UNIV OF MICHIGAN
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
InactiveUS20050124569A1Improves various propertyImprove the immunityCompounds screening/testingSpecial deliveryCXCR4Chemokine Receptor Gene
This invention relates to compounds, compositions, and methods useful for modulating chemokine receptor (CXCR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CXCR gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of CXCR genes such as CXCR4 and CXCR7A.
Owner:SIRNA THERAPEUTICS INC
Methods
InactiveUS20110044997A1Reduce unwanted side effectPreventing agonism of unnecessary targetsBiocideNervous disorderProgenitorCXCR4
The current invention provides a method for mobilising endothelial progenitor cells (EPC) and / or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.
Owner:IMPERIAL INNOVATIONS LTD
Methods and compositions for modulating the mobilization of stem cells
InactiveUS20070190023A1Enhance mobilizationPrevent egressBiocidePeptide/protein ingredientsDiseaseCXCR4
Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells from the bone marrow to the peripheral blood are disclosed. In particular, the invention relates to the use of adrenergic agonists that act in concert with a mobilization compound or agent. The mobilization agent(s) may act to decrease the expression or function of the chemokine, CXCL12, or may act to block or antagonize CXCR4. The invention also relates to methods of using these compounds or agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells is necessary for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating the symptoms associated with such diseases, disabilities or conditions. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed.
Owner:MT SINAI SCHOOL OF MEDICINE
Methods for detecting and treating kidney disease
A method is provided for diagnosing and monitoring kidney disease or a predisposition to kidney disease, in a subject comprising detecting pVHL, VEGF-A, CXCR4, integrin β-1, PDGF-A, HIF1α and / or TGFβ in a sample from the subject. Screening methods for test agents for inhibiting kidney disease, and therapeutic applications are also described.
Owner:MOUNT SINAI HOSPITAL
Methods to mobilize progenitor/stem cells
ActiveUS20050043367A1Expand the populationIncrease productionAntibacterial agentsBiocideProgenitorAryl
Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulaZ-linker-Z′ (1)or pharmaceutically acceptable salt thereof wherein Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z′ is of the formula—Ar(Y)j;wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0-3; and “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
Owner:GENZYME CORP
Dual vector for inhibition of human immunodeficiency virus
The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and / or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.
Owner:RGT UNIV OF CALIFORNIA +1
CXCR4 chemokine receptor binding compounds
ActiveUS7291631B2Inhibit HIV replicationDestroy effectivenessBiocideOrganic chemistryProgenitorCXCR4
The present invention relates to compounds that bind to chemokine receptors, and having the formulawherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.
Owner:GENZYME CORP
Chemokine receptor antagonists and use thereof
InactiveUS8168783B2Prevention and therapyBiocideSenses disorderArterial Occlusive DiseasesMental nerve
Owner:ONO PHARMA CO LTD
Streptococcus thermophilus derived human CXCR3 gene target sequence recognizable by CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated 9) system and sgRNA (single guide ribonucleic acid) and application thereof
InactiveCN105316324AAchieve preventionAchieve therapeutic effectOrganic active ingredientsHydrolasesProtein recruitmentA-DNA
The invention belongs to the field of genetic engineering, discloses a streptococcus thermophilus derived target sequence recognizable by a CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated 9) system and further discloses a sgRNA (single guide ribonucleic acid) and a coding DNA (deoxyribonucleic acid) molecule thereof. The target sequence is shown as n-20th of any one of SEQ ID NO:1-63, wherein n=1-5. A sequence of the sgRNA is 5'-recognition sequence- Cas9 protein recruitment sequence-3', and a DNA sequence corresponding to the recognition sequence is identical to the target sequence. The invention also discloses the CRISPR-Cas9 system, and the CRISPR-Cas9 system comprises Cas9 proteins and sgRNA and / or comprises carriers carrying a Cas9 protein coding sequence and a sgRNA coding sequence. The invention further discloses application of the CRISPR-Cas9 system to CXCR4 gene editing and preparation of medicines for treating HIV (human immunodeficiency virus) infection. CXCR4 gene editing can be realized to protect cells from HIV infection.
Owner:张竞方
Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.
Owner:GLYCOMIMETICS
Treatment of hematologic malignancies with an Anti-cxcr4 antibody
ActiveUS20140322208A1Inhibit capillary tube formationBoron compound active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsCXCR4Monoclonal antibody
The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure.
Owner:BRISTOL MYERS SQUIBB CO
Isolation and characterization of muscle regenerating cells
InactiveUS20060014287A1Useful for transplantationBiocideArtificial cell constructsSurface markerProgenitor
Populations enriched for myogenic progenitors are obtained by selection on the basis of expression of specific cell surface markers. The muscle progenitor cells are characterized as being CD45− and CD34+, and may further be characterized as lacking expression of Mac-1 (CD11b) and positive for expression of CXCR4 (CD184) and β1-integrin (CD29).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
sgRNA (singleguide Ribonucleic Acid), lentiviral vector constructed by the same and application thereof
InactiveCN106801056AEffective knockoutExcellent anti-virus infection abilityCell receptors/surface-antigens/surface-determinantsAntiviralsTreatment fieldHIV receptor
The invention relates to the field of gene therapy, in particular relates to sgRNA (singleguide Ribonucleic Acid), as well as a lentiviral vector constructed by the same and application thereof and specifically relates to sgRNA with SIVmac1A11 lentivirus as a framework to express SpCas9 protein and gene specificity. The sgRNA is applied to treating human and simian AIDS (Acquired Immune Deficiency Syndrome). A nucleotide sequence of the sgRNA is shown as SEQ ID NO.1 to 2. According to the sgRNA disclosed by the invention, a current most efficient CRISPR / Cas9 gene editing tool is utilized, a designed CXCR4 / CCR5 gene sgRNA locus has gene knockout activity superior to other loci reported by existing research, and the sgRNA is applied to gene therapy of SIV infected rhesus monkeys for the first time. Compared with ZFN and TALEN, the sgRNA has the advantages of being convenient to operate, low in cost and the like.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Compositions and methods for the treatment of ophthalmic disease
Owner:ALLERGAN INC
Anti-cxcr4 as a sensitizer to cancer therapeutics
ActiveUS20130216531A1Promote cell survivalPrevent infiltration of tumorBiocidePeptide/protein ingredientsCXCR4CXCR4 Inhibitor
Inhibition of CXCR4 can inhibit tumor growth and metastasis during certain therapeutic windows. Disclosed are novel methods for treating and preventing cancer in a subject related to administration of CXCR4 inhibitors during a therapeutic window following treatment with another anti-tumor therapy.
Owner:THE GENERAL HOSPITAL CORP
CXCR4 antagonists for the treatment of medical disorders
ActiveUS20070054930A1Reduce morbidityInhibit transferBiocideOrganic compound preparationDiseaseMedical disorder
The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.
Owner:EMORY UNIVERSITY
Compound having acidic group which may be protected, and use thereof
A compound represented by general formula (I):a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification. The compound of the present invention has antagonistic activity against CXCR4 and is therefore useful as a preventive and / or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Owner:ONO PHARMA CO LTD
CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
InactiveUS20080227799A1Inhibit transferReduce the possibilityBiocideOrganic active ingredientsMedical disorderDisease
The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.
Owner:LIOTTA DENNIS C +2
Genetically engineered cells for therapeutic applications
InactiveUS20050271639A1Increased longevityImprove survivabilityBiocidePeptide/protein ingredientsCXCR4Mesenchymal stem cell
An isolated mesenchymal stem cell, multipotent adult progenitor cell, or other stem cells is genetically modified to express at least one of CXCR4, SDF-1, or a variant thereof.
Owner:THE CLEVELAND CLINIC FOUND
Genetically engineered cells for therapeutic applications
InactiveUS20070224171A1Improve survivabilityReduce apoptosisBiocidePeptide/protein ingredientsCXCR4Mesenchymal stem cell
Owner:PENN MARC S +1
Vascularization Inhibitors
InactiveUS20130236889A1Increased vascularizationPeptide/protein ingredientsMicrobiological testing/measurementCXCR4Knockout animal
This invention provides a therapeutic agent for inhibiting neovascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, and a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4.Based on the finding that vascularization is suppressed in CXCR4 knockout mice, it becomes possible to prepare a therapeutic agent for suppressing vascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, each of which comprises as the effective ingredient, a substance that inhibits the action of CXCR4, as well as to prepare a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Methods for treatment are made possible that use these therapeutic agents.
Owner:KISHIMOTO TADAMITSU +2
GRNA, expression vector, knockout system and kit for knocking out CXCR4 gene
InactiveCN107893074AEffective knockoutHigh feasibilityHydrolasesStable introduction of DNACXCR4Co-receptor
The invention discloses a gRNA, a knockout system and a kit for knocking out CXCR4 gene. A target site with high cutting efficiency is screened, the gRNA specifically targeting a target gene is designed and prepared, the CXCR4 gene can be effectively knocked out by CRISPR-Cas9 technology, HIV virus co-receptor CXCR4 on cell surface can be knocked out by CRISPR-nickase gene editing technology, theoff-target efficiency can be greatly reduced under the premise of effective CXCR4 gene knockout, the feasibility of clinical use is improved, and security risks can be reduced.
Owner:广东赤萌医疗科技有限公司
Identification Of Novel Cell Surface Markers For Pancreatic Progenitor Cells And Definite Endodermal Cells
InactiveUS20130309769A1Microbiological testing/measurementPancreatic cellsEndoderm cellPancreatic progenitor cell
Methods of identifying, isolating and qualifying pancreatic progenitor cells and definite endodermal cells. An isolated population of pancreatic progenitor cells, including at least 75% of cells having a TROP-2+ and / or TROP-2+ / GPR50+ expression pattern and an isolated population of definite endodermal cells, including at least 50% of cells having aSOX17+ / SOX7+ / GSC+ / CER+ / FOXA2+ / CXCR4+ / NANOG expression pattern. Nucleic acid constructs including a reporter protein under the transcriptional regulation of SOX17 regulatory sequence or of PDX1 regulatory sequence, and cells comprising same, and methods and kits using same.
Owner:STEM CELL THERAPEUTICS
Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and / or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
Owner:CHEMOCENTRYX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com